SI2079688T1 - Spojine glukagon receptorskih antagonistov, sestavki vsebujoči take spojine in njihova farmacevtska raba - Google Patents

Spojine glukagon receptorskih antagonistov, sestavki vsebujoči take spojine in njihova farmacevtska raba

Info

Publication number
SI2079688T1
SI2079688T1 SI200731049T SI200731049T SI2079688T1 SI 2079688 T1 SI2079688 T1 SI 2079688T1 SI 200731049 T SI200731049 T SI 200731049T SI 200731049 T SI200731049 T SI 200731049T SI 2079688 T1 SI2079688 T1 SI 2079688T1
Authority
SI
Slovenia
Prior art keywords
compounds
compositions containing
receptor antagonist
pharmaceutical use
glucagon receptor
Prior art date
Application number
SI200731049T
Other languages
English (en)
Inventor
John E. Stelmach
Emma R. Parmee
James R. Tata
Keith G. Rosauer
Ronald M. Kim
Amy R. Bittner
Jiang Chang
Christopher Joseph Sinz
Original Assignee
Merck Sharp & Dohme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38982644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2079688(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp filed Critical Merck Sharp & Dohme Corp
Publication of SI2079688T1 publication Critical patent/SI2079688T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
SI200731049T 2006-10-03 2007-09-27 Spojine glukagon receptorskih antagonistov, sestavki vsebujoči take spojine in njihova farmacevtska raba SI2079688T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84896706P 2006-10-03 2006-10-03
EP07838940A EP2079688B1 (en) 2006-10-03 2007-09-27 Glucagon receptor antagonist compounds, compositions containing such compounds and their pharmaceutical use
PCT/US2007/020858 WO2008042223A1 (en) 2006-10-03 2007-09-27 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
SI2079688T1 true SI2079688T1 (sl) 2012-12-31

Family

ID=38982644

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731049T SI2079688T1 (sl) 2006-10-03 2007-09-27 Spojine glukagon receptorskih antagonistov, sestavki vsebujoči take spojine in njihova farmacevtska raba

Country Status (30)

Country Link
US (3) US20100004158A1 (sl)
EP (1) EP2079688B1 (sl)
JP (1) JP2010505828A (sl)
KR (1) KR20090076907A (sl)
CN (1) CN101535252A (sl)
AR (1) AR063022A1 (sl)
AU (1) AU2007305430B2 (sl)
BR (1) BRPI0717305A2 (sl)
CA (1) CA2664004C (sl)
CL (1) CL2007002841A1 (sl)
CO (1) CO6190512A2 (sl)
CR (1) CR10694A (sl)
DK (1) DK2079688T3 (sl)
EA (1) EA017800B1 (sl)
EC (1) ECSP099225A (sl)
ES (1) ES2390296T3 (sl)
GE (1) GEP20125506B (sl)
IL (1) IL197788A0 (sl)
MA (1) MA31963B1 (sl)
MX (1) MX2009003611A (sl)
NO (1) NO342172B1 (sl)
PE (1) PE20080676A1 (sl)
PL (1) PL2079688T3 (sl)
PT (1) PT2079688E (sl)
SI (1) SI2079688T1 (sl)
TN (1) TN2009000111A1 (sl)
TW (1) TW200821284A (sl)
UA (1) UA96308C2 (sl)
WO (1) WO2008042223A1 (sl)
ZA (1) ZA200901694B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548128A (en) * 2003-12-29 2010-05-28 Banyu Pharma Co Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
US7989472B2 (en) * 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2650619A1 (en) * 2006-05-16 2007-11-29 Merck And Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2009220615B2 (en) 2008-03-05 2013-12-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2009246424A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
PL2799428T3 (pl) 2008-08-13 2017-05-31 Metabasis Therapeutics, Inc. Antagoniści glukagonu
EP2346830B1 (en) * 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012504630A (ja) * 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
WO2010071750A1 (en) * 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US8697740B2 (en) 2009-01-12 2014-04-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) * 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
DK2673260T3 (en) 2011-02-08 2016-10-10 Pfizer Glucagonreceptormodulator
EP2734503B1 (en) * 2011-07-22 2015-09-16 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
EP3065736B1 (en) * 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN107304180B (zh) * 2016-04-22 2022-04-29 浙江海正药业股份有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
CN109071420B (zh) * 2016-06-14 2021-06-18 上海昂睿医药技术有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
CN107759522B (zh) * 2016-08-15 2023-04-14 浙江海正药业股份有限公司 羧酸类衍生物、其制备方法及其在医药上的用途
KR20240110661A (ko) 2016-08-30 2024-07-15 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
WO2019040471A1 (en) 2017-08-22 2019-02-28 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑
CN112608378B (zh) * 2020-12-09 2023-09-08 江苏师范大学 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514651A (ja) 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド 置換ピリジルピロール、前記化合物を含む組成物及び使用方法
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
CA2271941A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
AU728760B2 (en) 1996-11-20 2001-01-18 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
AU755421B2 (en) 1997-12-19 2002-12-12 Amgen, Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
EP1183229B1 (en) 1999-05-17 2005-10-26 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
CA2411552A1 (en) 2000-06-23 2002-01-03 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1381592A1 (en) * 2001-04-13 2004-01-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused compounds
MXPA04002590A (es) * 2001-09-18 2004-06-18 Hoffmann La Roche Agonistas retinoides i de alquil urea.
WO2003048109A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Novel glucagon antagonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
WO2003064404A1 (fr) 2002-02-01 2003-08-07 Dainippon Pharmaceutical Co., Ltd. Hydrazides d'acide 2-furancarboxylique et compositions pharmaceutiques les contenant
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
PT1537078E (pt) * 2002-08-29 2010-06-18 Merck Sharp & Dohme Indoles que possuem actividade antidiabética
WO2006102067A1 (en) * 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
PE20080676A1 (es) 2008-06-12
AR063022A1 (es) 2008-12-23
MA31963B1 (fr) 2011-01-03
UA96308C2 (ru) 2011-10-25
EA200970342A1 (ru) 2009-10-30
WO2008042223A1 (en) 2008-04-10
TW200821284A (en) 2008-05-16
US7968589B2 (en) 2011-06-28
EA017800B1 (ru) 2013-03-29
US20100144824A1 (en) 2010-06-10
CA2664004C (en) 2013-07-23
KR20090076907A (ko) 2009-07-13
MX2009003611A (es) 2009-04-22
TN2009000111A1 (en) 2010-08-19
AU2007305430A1 (en) 2008-04-10
EP2079688A1 (en) 2009-07-22
CA2664004A1 (en) 2008-04-10
CL2007002841A1 (es) 2008-02-08
DK2079688T3 (da) 2012-11-05
GEP20125506B (en) 2012-04-25
US7687534B2 (en) 2010-03-30
US20100004158A1 (en) 2010-01-07
ES2390296T3 (es) 2012-11-08
CR10694A (es) 2009-05-25
CO6190512A2 (es) 2010-08-19
ZA200901694B (en) 2010-01-27
PT2079688E (pt) 2012-11-22
NO342172B1 (no) 2018-04-09
ECSP099225A (es) 2009-07-31
CN101535252A (zh) 2009-09-16
PL2079688T3 (pl) 2013-01-31
AU2007305430B2 (en) 2011-07-21
BRPI0717305A2 (pt) 2014-03-25
EP2079688B1 (en) 2012-07-25
IL197788A0 (en) 2009-12-24
US20080085926A1 (en) 2008-04-10
NO20091734L (no) 2009-06-04
JP2010505828A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
SI2079688T1 (sl) Spojine glukagon receptorskih antagonistov, sestavki vsebujoči take spojine in njihova farmacevtska raba
EP1868985A4 (en) GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND METHODS OF USE
EP2054411A4 (en) NOVEL COMPOUNDS, ISOMERS THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IL194642A0 (en) Antagonist anti-cd40 antibody pharmaceutical compositions
IL193894A0 (en) Pharmaceutical compositions containing luliconazole for external use
ZA200808530B (en) Pharmaceutical composition for external use
EP2121658A4 (en) PIPERAZINYLPROPYLPYRAZOL DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP2058304A4 (en) P2X4 RECEPTOR ANTAGONIST
EP2281557A4 (en) PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
PL1951661T3 (pl) Antagoniści receptora glukagonu, wytwarzanie i terapeutyczne zastosowania
PT2129654E (pt) Antagonistas do receptor de glucagina
SI1951658T1 (sl) Antagonisti glukagonskega receptorja priprava interapevtska uporaba
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
IL194734A0 (en) Pharmaceutical compositions containing opioid antagonists
EP1808446A4 (en) IL-18 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION WITH THE ANTAGONIST
IL200885A (en) A history of mannich-based compounds and pharmacological preparations including them
EP2205218A4 (en) ESOMEPRAZOLE-CONTAINING PHARMACEUTICAL COMPOSITION
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
EP2238105A4 (en) NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
HUP0700269A2 (en) Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
IL218745A0 (en) Pharmaceutical compositions containing roflumilast
IL205949A0 (en) 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
EP2109454A4 (en) PHARMACEUTICAL COMPOSITIONS BASED ON GLP-1